相关实验视频

Updated: Sep 11, 2025

Lipid Supplementation for Longevity and Gene Transcriptional Analysis in Caenorhabditis elegans

Lipid Supplementation for Longevity and Gene Transcriptional Analysis in Caenorhabditis elegans

Published on: December 9, 2022

塞马格卢提德减缓了艾滋病毒相关脂肪过高症患者的表观遗传衰老:来自随机对照试验的证据

Michael J Corley¹, Varun Dwaraka², Alina Ps Pang³

¹University of California San Diego, Department of Medicine, Division of Geriatrics and Palliative Care, La Jolla, CA, USA.

medRxiv : the preprint server for health sciences

|August 12, 2025

概括

作为GLP-1受体激动剂的塞马格卢提德,显著地逆转了艾滋病毒相关的脂肪缩的成年人的表观遗传衰老标志物. 这项研究提供了第一个临床试验证据,表明西马格卢可能会减缓生物衰老过程.

科学领域:

老年学是指老年学的学科.
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.
药理学药理学是指药理学的学科.

背景情况:

葡萄糖类-1 (GLP-1) 受体激动剂正在探索治疗潜力.
之前没有关于赛马格卢提德对表观遗传衰老标志物的影响的数据.
与艾滋病毒相关的脂质增大症为衰老研究提供了一个独特的背景.

研究的目的:

为了研究塞马格卢提德对艾滋病毒相关的脂质缩成年人的表观遗传衰老的影响.
为了评估赛马格卢提德对多个经过验证的基于DNA甲基化的衰老钟的影响.
为了确定塞马格卢提德是否会影响生物衰老的速度.

主要方法:

对一项为期32周,双盲,安慰剂控制的2b期试验的后期分析.
从接受塞马格卢提德 (n=45) 或安慰剂 (n=39) 的参与者中对外周围血液甲基组的分析.
对多个表观遗传衰老时钟的评估,包括GrimAge,PhenoAge,DunedinPACE,OMICmAge和RetroAge,并对共变量进行调整.

主要成果:

在多个时钟中,塞马格卢提德显著降低了表观遗传年龄,包括PCGrimAge (-3.1年),GrimAge V1 (-1.4年),GrimAge V2 (-2.3年),PhenoAge (-4.9年) 和DunedinPACE (-0.09单位,速度减慢了~9%).
该药物还减少了OMICmAge时钟 (-2.2年) 和RetroAge时钟 (-2.2年).
11个器官系统时钟显示,semaglutide减缓了衰老,特别是炎症,大脑和心脏,而内在容量时钟保持不变.

结论:

赛马格卢提德在减缓表观遗传衰老生物标志物方面表现出显著的影响.
这些发现代表了第一个临床试验证据,证明西马格卢提德能调节表观遗传衰老.
需要对GLP-1受体激动剂的进一步研究,以延长健康寿命.

关键词:

通过DNA甲基化.基因表观时钟是什么?表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.艾滋病病毒艾滋病病毒艾滋病病毒塞马格卢提德 (semaglutide) 是一种类型的老化的老化衰老的老化临床试验临床试验临床试验临床试验临床试验

更多相关视频

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

Peptide-based Identification of Functional Motifs and their Binding Partners

Peptide-based Identification of Functional Motifs and their Binding Partners

Published on: June 30, 2013

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...